FBIO

Fortress Biotech (FBIO)

Fortress Biotech Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:FBIO

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/22	05 : 01	GlobeNewswire Inc.	Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:FBIO	Fortress Biotech Inc
2024/06/20	21 : 30	GlobeNewswire Inc.	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	NASDAQ:FBIO	Fortress Biotech Inc
2024/06/20	21 : 00	GlobeNewswire Inc.	Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:FBIO	Fortress Biotech Inc
2024/06/17	21 : 30	GlobeNewswire Inc.	Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/16	21 : 30	GlobeNewswire Inc.	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/16	21 : 00	GlobeNewswire Inc.	Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/16	05 : 15	GlobeNewswire Inc.	Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/16	05 : 01	GlobeNewswire Inc.	Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/15	21 : 30	GlobeNewswire Inc.	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/14	21 : 30	GlobeNewswire Inc.	Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/14	05 : 01	GlobeNewswire Inc.	Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/07	21 : 30	GlobeNewswire Inc.	Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/03	05 : 01	GlobeNewswire Inc.	Mustang Bio Announces Closing of $4 Million Public Offering	NASDAQ:FBIO	Fortress Biotech Inc
2024/05/02	05 : 01	GlobeNewswire Inc.	Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	NASDAQ:FBIO	Fortress Biotech Inc
2024/04/30	09 : 00	GlobeNewswire Inc.	Mustang Bio Announces Pricing of $4 Million Public Offering	NASDAQ:FBIO	Fortress Biotech Inc
2024/04/29	21 : 00	GlobeNewswire Inc.	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	NASDAQ:FBIO	Fortress Biotech Inc
2024/04/25	21 : 30	GlobeNewswire Inc.	Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	NASDAQ:FBIO	Fortress Biotech Inc
2024/04/24	20 : 30	GlobeNewswire Inc.	Avenue Therapeutics Announces Reverse Stock Split	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/29	05 : 05	GlobeNewswire Inc.	Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/28	22 : 00	GlobeNewswire Inc.	Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/25	21 : 30	GlobeNewswire Inc.	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/22	05 : 01	GlobeNewswire Inc.	Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/19	05 : 05	GlobeNewswire Inc.	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/18	21 : 30	GlobeNewswire Inc.	Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/15	21 : 30	GlobeNewswire Inc.	Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/15	21 : 15	GlobeNewswire Inc.	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/13	21 : 30	GlobeNewswire Inc.	Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/12	21 : 30	GlobeNewswire Inc.	Fortress Biotech to Participate in 36th Annual ROTH Conference	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/11	21 : 30	GlobeNewswire Inc.	Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	NASDAQ:FBIO	Fortress Biotech Inc
2024/03/11	21 : 00	GlobeNewswire Inc.	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	NASDAQ:FBIO	Fortress Biotech Inc